<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-IL121FKA/696a4233-75ae-4f80-9dda-9b8adbf17121/PDF"><dcterms:extent>455 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-IL121FKA/dc66ef1d-a471-4e9d-a958-309fee8cecc9/TEXT"><dcterms:extent>0 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-IL121FKA"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2024</dcterms:issued><dc:creator>Baumgartner, Ana</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:75</dc:format><dc:format xml:lang="sl">str. 34-42</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:192524035</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-IL121FKA</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">bolnikom prijazne farmacevtske oblike</dc:subject><dc:subject xml:lang="en">coprocessed excipients</dc:subject><dc:subject xml:lang="en">direct compression</dc:subject><dc:subject xml:lang="sl">direktno stiskanje</dc:subject><dc:subject xml:lang="sl">Etika</dc:subject><dc:subject xml:lang="sl">Farmacevtske oblike</dc:subject><dc:subject xml:lang="sl">koprocesirane pomožne snovi</dc:subject><dc:subject xml:lang="en">orodispersible tablets</dc:subject><dc:subject xml:lang="sl">orodisperzibilne tablete</dc:subject><dc:subject xml:lang="en">patient-friendly dosage forms</dc:subject><dc:subject xml:lang="sl">Tablete</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Uporaba koprocesiranih pomonih snovi pri izdelavi orodisperznibilnih tablet| Use of coprocessed excipients in orodispersible tablets|</dc:title><dc:description xml:lang="sl">In the last years, there is a growing tendency for development of patient-friendly dosage forms. Among these, orodispersible tablets show great potential, as they disintegrate in the oral cavity before patients swallow them, which can improve patient compliance. The simplest and economically favourable approach for their production is direct compression. However, this requires the powder blend to have adequate properties, which can be achieved by implementing coprocessed excipients. These are a mixture of more excipients, in which physical properties of separate components are altered in a way that is not achievable by simple physical blending, and without any significant chemical changes. There are already a few coprocessed excipients on the market, intended for production of orodispersible tablets by direct compression. Nevertheless, it has to be acknowledged that the price of coprocessed excipients is still higher than for one-component excipients and that their registration is more complicated from a regulatory perspective</dc:description><dc:description xml:lang="sl">V zadnjih letih dajemo v farmacevtskem razvoju vse več poudarka na razvoj bolnikom prijaznih farmacevtskih oblik. Mednje spadajo tudi orodisperzibilne tablete, ki v ustih razpadejo, še preden jih bolniki pogoltnejo. S tem lahko ključno prispevamo k sodelovanju bolnikov pri zdravljenju. Najbolj enostaven in stroškovno ugoden način izdelave orodisperzibilnih tablet je direktno stiskanje, za kar pa potrebujemo zmes prahov za tabletiranje z ustreznimi lastnostmi. Pri tem nam lahko pomaga uporaba koprocesiranih pomožnih snovi. V njih je združenih več posameznih pomožnih snovi, s čimer se njihove fizikalne lastnosti spremenijo na način, ki ga ni mogoče doseči s preprostim fizikalnim mešanjem, ter brez bistvenih kemijskih sprememb. Na trgu že obstaja več koprocesiranih pomožnih snovi, ki so posebej namenjene za izdelavo orodisperzibilnih tablet z direktnim stiskanjem. Poudariti pa je treba, da je cena koprocesiranih snovi še vedno višja kot pri enostavnih pomožnih snoveh ter da je pridobivanje dovoljenja za promet tovrstnega zdravila bolj zapleteno</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-IL121FKA"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-IL121FKA" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-IL121FKA/696a4233-75ae-4f80-9dda-9b8adbf17121/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-IL121FKA/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-IL121FKA" /></ore:Aggregation></rdf:RDF>